DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity.

Life Sciences
Kai-Chia YehChiung-Tong Chen

Abstract

Dipeptidyl peptidase 4 (DPP-4) is a valid molecular drug target from which its inhibitors have been developed as medicines for treating diabetes. The present study evaluated a new synthetic DPP-4-specific inhibitor of small molecule DBPR108 for pharmacology and pharmacokinetic profiles. DBPR108 of various doses was orally administered to rats, diabetic mice, and dogs and the systemic circulating DPP-4 activities in the animals were measured to demonstrate the pharmacological mechanisms of action via DPP-4 inhibition. Upon an oral administration of DBPR108, the serum active GLP-1 and insulin levels of the rats challenged with an oral glucose ingestion were measured. Oral glucose tolerance test in diet-induced obese mice was performed to examine if DBPR108 increases the glucose tolerability in animals. Orally administered DBPR108 inhibited the systemic plasma DPP-4 activities in rats, dogs and diabetic mice in a dose-dependent manner. DBPR108 caused elevated serum levels of active GLP-1 and insulin in the rats. DBPR108 dose-dependently increased the glucose tolerability in diet-induced obese (DIO) mice and, furthermore, DIO mice treated with DBPR108 (0.1 mg/kg) in combination with metformin (50 or 100 mg/kg) showed a prominently ...Continue Reading

References

Oct 22, 1998·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·B Ahrén
Sep 30, 2003·Diabetes Care·Daniel J Drucker
Jun 8, 2004·The Journal of Clinical Endocrinology and Metabolism·Jean-Pierre GutzwillerChristoph Beglinger
Oct 27, 2004·Diabetes Care·John B BuseUNKNOWN Exenatide-113 Clinical Study Group
Apr 17, 2007·Bioorganic & Medicinal Chemistry Letters·Dooseop KimAnn E Weber
Dec 7, 2007·Best Practice & Research. Clinical Endocrinology & Metabolism·Brian D Green, Peter R Flatt
Oct 28, 2008·Biochemical and Biophysical Research Communications·Sara Bohman, Aileen J F King
Dec 11, 2008·Vascular Health and Risk Management·Bernd RichterChristian Lerch
Apr 24, 2010·Pharmacotherapy·Joshua J NeumillerR Keith Campbell
May 3, 2011·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Jennifer S ByrdGailen D Marshall
Jul 23, 2013·Indian Journal of Endocrinology and Metabolism·Vishal Gupta
Aug 21, 2013·Pharmacoepidemiology and Drug Safety·Mónica TarapuésAlbert Figueras
Aug 6, 2015·Scientific Reports·Ruijun HanJohn W Osborn
Aug 23, 2019·Diabetes Technology & Therapeutics·John D BucheitEvan M Sisson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.